Blinding Them With Science: Genentech Tries To Win Shareholders Over
Executive Summary
Genentech's March 2 presentation to analysts and investors - a four hour plus love-in dominated by talk of peptides and pathways - seems to have worked
You may also be interested in...
Genentech's New Deal Maker
In a wide-ranging interview just four days after joining Genentech, the biotech's new head of business development outlines his team's mission, which emphasizes early-stage novel assets arising from academia and biotech.
Roche Wins Genentech, But Will Biotech Employees Remain?
After eight months of haggling, Roche finally struck a deal to pay $95 a share for Genentech, an iconic biotech in which the drug maker already owns a 56 percent stake
Roche Wins Genentech, But Will Biotech Employees Remain?
After eight months of haggling, Roche finally struck a deal to pay $95 a share for Genentech, an iconic biotech in which the drug maker already owns a 56 percent stake